Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spindlin-1 is a chromatin reader protein encoded by the SPIN1 gene in humans. It contains three Tudor-like domains that specifically recognize and bind to histone H3 trimethylated at lysine 4 (H3K4me3) and lysine 9 (H3K9me3), integrating into the regulation of chromatin structure and gene transcription[2][4][6]. Spindlin-1 acts as a transcriptional co-activator, promotes expression of rRNA genes, and is implicated in cell cycle control[1][2]. It is highly expressed in certain cancer cells, such as ovarian cancer, and has been identified as a putative oncogene[1][4]. The protein localizes mainly to the nucleolus and at rDNA loci, participating in selective transcriptional activation. Small molecule inhibitors have been developed to target its Tudor domains, representing a potential therapeutic strategy for cancer where SPIN1 is dysregulated[4].
Inhibition of chromatin reader function by blocking Tudor domain-mediated recognition of methylated histone marks Modulation of gene transcription via disruption of chromatin effector complexes
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spindlin-1 (SPIN1).